BOSTON — An increase in immune checkpoint proteins was observed in metastatic melanoma patients treated with topical diphencyprone, according to a study presented at the American Academy of Dermatology Annual Meeting.
“Diphencyprone, or DCPD for short, has been used for many years to treat various dermatologic conditions including alopecia areata and warts, but more recently it’s been used as a treatment for cutaneous metastases of melanoma,” Nicholas Gulati, MD, PhD, assistant professor of dermatology at the Icahn School of Medicine and director of both the